Patient and physician perspectives on the use of cyclosporine ophthalmic emulsion 0.05% for the management of chronic dry eye

Figures & data

Table 1 CsA and dry eye – different study designs

Study type	References
Meta-analysis/systematic review	(^Citation8, ^Citation18, ^Citation19)
Randomized controlled trial	(^Citation14, ^Citation15, ^Citation17, ^Citation25, ^Citation42, ^Citation43, ^Citation47, ^Citation60)
Prospective observational studies	(^Citation20, ^Citation21, ^Citation26, ^Citation30, ^Citation36, ^Citation53, ^Citation56^–^Citation58)
Retrospective	(^Citation33, ^Citation39, ^Citation41, ^Citation46)
Clinician perspectives	(^Citation14, ^Citation23, ^Citation39)
Patient surveys	(^Citation29, ^Citation35)
Health expenditure data	(^Citation12, ^Citation51)

Abbreviation: CsA, cyclosporine A.

SacchettiMMantelliFLambiaseAMastropasquaAMerloDBoniniSSystematic review of randomized clinical trials on topical ciclosporin A for the treatment of dry eye diseaseBr J Ophthalmol20149881016102224344232

 PubMed Web of Science ®Google Scholar

ZhouXQWeiRLTopical cyclosporine A in the treatment of dry eye: a systematic review and meta-analysisCornea201433776076724815112

 PubMed Web of Science ®Google Scholar

WanKHChenLJYoungALEfficacy and safety of topical 0.05% cyclosporine eye drops in the treatment of dry eye syndrome: a systematic review and meta-analysisOcul Surf201513321322526045239

 PubMed Web of Science ®Google Scholar

SallKStevensonODMundorfTKReisBLTwo multicenter, randomized studies of the efficacy and safety of cyclosporine ophthalmic emulsion in moderate to severe dry eye disease. CsA Phase 3 Study GroupOphthalmology2000107463163910768324

 PubMed Web of Science ®Google Scholar

StevensonDTauberJReisBLEfficacy and safety of cyclosporin A ophthalmic emulsion in the treatment of moderate-to-severe dry eye disease: a dose-ranging, randomized trial. The Cyclosporin A Phase 2 Study GroupOphthalmology2000107596797410811092

 PubMed Web of Science ®Google Scholar

ChenMGongLSunXA comparison of cyclosporine 0.05% ophthalmic emulsion versus vehicle in Chinese patients with moderate to severe dry eye disease: an eight-week, multicenter, randomized, double-blind, parallel-group trialJ Ocul Pharmacol Ther201026436136620698799

 PubMed Web of Science ®Google Scholar

ParkYSongJSChoiCYYoonKCLeeHKKimHSA randomized multicenter study comparing 0.1%, 0.15%, and 0.3% sodium hyaluronate with 0.05% cyclosporine in the treatment of dry eyeJ Ocul Pharmacol Ther2017332667227929721

 PubMed Web of Science ®Google Scholar

ByunYJKimTIKwonSMEfficacy of combined 0.05% cyclosporine and 1% methylprednisolone treatment for chronic dry eyeCornea201231550951319730097

 PubMed Web of Science ®Google Scholar

LeonardiAVan SettenGAmraneMEfficacy and safety of 0.1% cyclosporine A cationic emulsion in the treatment of severe dry eye disease: a multicenter randomized trialEur J Ophthalmol201626428729627055414

 PubMed Web of Science ®Google Scholar

RaoSNTopical cyclosporine 0.05% for the prevention of dry eye disease progressionJ Ocul Pharmacol Ther201026215716420415623

 PubMed Web of Science ®Google Scholar

PrabhasawatPTesavibulNMahawongWA randomized double-masked study of 0.05% cyclosporine ophthalmic emulsion in the treatment of meibomian gland dysfunctionCornea201231121386139323135530

 PubMed Web of Science ®Google Scholar

PerryHDSolomonRDonnenfeldEDEvaluation of topical cyclosporine for the treatment of dry eye diseaseArch Ophthalmol200812681046105018695097

 PubMedGoogle Scholar

StonecipherKGTorkildsenGLOuslerGW3rdMorrisSVillanuevaLHollanderDAThe IMPACT study: a prospective evaluation of the effects of cyclosporine ophthalmic emulsion 0.05% on ocular surface staining and visual performance in patients with dry eyeClin Ophthalmol20161088789527257373

 PubMed Web of Science ®Google Scholar

YangJMChoiWKimNYoonKCComparison of topical cyclosporine and diquafosol treatment in dry eyeOptom Vis Sci2015929e296e30226107023

 PubMed Web of Science ®Google Scholar

ByunYSRhoCRChoKChoiJANaKSJooCKCyclosporine 0.05% ophthalmic emulsion for dry eye in Korea: a prospective, multicenter, open-label, surveillance studyKorean J Ophthalmol201125636937422131772

 PubMedGoogle Scholar

BarberLDPflugfelderSCTauberJFoulksGNPhase III safety evaluation of cyclosporine 0.1% ophthalmic emulsion administered twice daily to dry eye disease patients for up to 3 yearsOphthalmology2005112101790179416102833

 PubMed Web of Science ®Google Scholar

PrabhasawatPTesavibulNKarnchanachetaneeCKasemsonSEfficacy of cyclosporine 0.05% eye drops in Stevens Johnson syndrome with chronic dry eyeJ Ocul Pharmacol Ther201329337237723289903

 PubMed Web of Science ®Google Scholar

JadidiKPanahiYEbrahimiAMafiMNejatFSahebkarATopical cyclosporine a for treatment of dry eye due to chronic mustard gas injuryJ Ophthalmic Vis Res20149441742225709764

 PubMedGoogle Scholar

ChungYWOhTHChungSKThe effect of topical cyclosporine 0.05% on dry eye after cataract surgeryKorean J Ophthalmol201327316717123730108

 PubMedGoogle Scholar

DastjerdiMHHamrahPDanaRHigh-frequency topical cyclosporine 0.05% in the treatment of severe dry eye refractory to twice-daily regimenCornea200928101091109619770713

 PubMed Web of Science ®Google Scholar

MahFMilnerMYiuSDonnenfeldEConwayTMHollanderDAPERSIST: Physician’s evaluation of Restasis((R)) satisfaction in second trial of topical cyclosporine ophthalmic emulsion 0.05% for dry eye: a retrospective reviewClin Ophthalmol201261971197623226002

 PubMedGoogle Scholar

SheppardJDScoperSVSamudreSTopical loteprednol pretreatment reduces cyclosporine stinging in chronic dry eye diseaseJ Ocul Pharmacol Ther2011271232721133792

 PubMed Web of Science ®Google Scholar

WilsonSEPerryHDLong-term resolution of chronic dry eye symptoms and signs after topical cyclosporine treatmentOphthalmology20071141767917070588

 PubMed Web of Science ®Google Scholar

WilliamsonJFHuynhKWeaverMADavisRMPerceptions of dry eye disease management in current clinical practiceEye Contact Lens201440211111524508770

 PubMed Web of Science ®Google Scholar

StonecipherKPerryHDGrossRHKerneyDLThe impact of topical cyclosporine A emulsion 0.05% on the outcomes of patients with keratoconjunctivitis siccaCurr Med Res Opin20052171057106316004673

 PubMed Web of Science ®Google Scholar

TrattlerWKatsevDKerneyDSelf-reported compliance with topical cyclosporine emulsion 0.05% and onset of the effects of increased tear production as assessed through patient surveysClin Ther200628111848185617213005

 PubMed Web of Science ®Google Scholar

StonecipherKGChiaJOnyenwenyiAVillanuevaLHollanderDAHealth claims database study of cyclosporine ophthalmic emulsion treatment patterns in dry eye patientsTher Clin Risk Manag2013940941524179335

 PubMed Web of Science ®Google Scholar

GalorAZhengDDArheartKLDry eye medication use and expenditures: data from the medical expenditure panel survey 2001 to 2006Cornea201231121403140722895158

 PubMed Web of Science ®Google Scholar